Regeneron Pharmaceuticals (REGN) said Tuesday it will boost its American manufacturing footprint by partnering with Fujifilm Diosynth Biotechnologies to produce biologics at a new North Carolina site.
The long-term agreement grants Regeneron access to Fujifilm's recently built biopharma facility in Holly Springs, the company said, nearly doubling its current large-scale manufacturing volume in the US.
The project, set to begin with an immediate technology transfer, represents a total investment of more than $3 billion over ten years, Regeneron said.
Regeneron said it is advancing multiple initiatives in New York, including a $3.6 billion expansion in Tarrytown, a fill-and-finish plant in Rensselaer, and a newly acquired property in Saratoga Springs for future growth.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。